New Stargardt treatments: MD Stem Cells SCOTS2 or ALK-001 Vitamin A

New Stargardt treatments: MD Stem Cells SCOTS2 or ALK-001 Vitamin A

Retina Stargardt

SCOTS2 eye treatment showing bone marrow separation and orbital placement of stem cells

SCOTS2 Eye Treatment

Comparison of new treatments for Stargardt macular dystrophy

MD Stem Cells continues to treat different retinal and optic nerve diseases on SCOTS2 with positive results.”

—Steven Levy MD

United States, November 10, 2022 / — Stargardt disease (SGTD) is an inherited retinal disease caused by mutations in the ABCA4 gene, which affects the processing of vitamin A. The accumulation of these byproducts is believed to be the cause of retinal cell damage. retina and blindness.
The study of ophthalmological treatment with stem cells II or SCOTTISH2 has achieved remarkable success in treating many eye diseases, including Stargardt. Developed by MD Stem Cells, the procedure uses a patient’s own bone marrow stem cells (BMSCs) to treat diseases of the retina and optic nerve. BMSCs have been shown to protect other cells and help block cell death in those that are stressed. BMSCs have also been shown to convert to certain cells in the retina.

MD Stem Cells treated Stargardt patients at SCOTS. A high percentage had improved binocular vision or their vision remained stable at follow-up. Access his published article on Stargardt disease understand these very positive results.
A separate company modified vitamin A into a drug called ALK-001. They treated a group of patients with ALK-001 once a day for 2 years to see if this would help prevent spots on the retina called atrophy.

In SCOTS, the endpoint (what was being measured) was the patient’s vision or visual acuity. 94.1% of patients showed improved or stable vision in both eyes at the one-year follow-up period. A total of 85.3% of treated eyes showed benefit, with 61.8% showing visual improvement and 23.5% remaining stable at follow-up. The results were statistically significant – the gold standard in medicine showing that the procedure was responsible for the benefits. There were no adverse events or complications with treatment.

In the Study ALK-001, the researchers used change in atrophy and not vision as the endpoint. ALK-001 did not completely stop atrophy, but did slow it by 21% over the 2-year study, or 0.35 mm2 in one year (similar size to the small zero at the % sign). The vision did not change.

The Ophthalmology Stem Cell Treatment Study II (SCOTS2) uses a patient’s own stem cells for treatment. A small portion of the patient’s bone marrow is taken, the active stem cell population is separated, and the patient is treated with 2 eye injections followed by an IV, all under a short period of anesthesia, so there is no pain. There is strong and statistically significant evidence that treatment can improve visual acuity or stop loss. SCOTS2 is a procedure. All accepted patients receive treatment; there is no sham or placebo group.

ALK-001 is a new drug. The drug is not yet approved by the FDA and is only available in clinical study. In the report, a placebo (pill with no medicine) was used in some of the patients who enrolled. It is common for drug studies to have placebo groups in which patients and doctors do not know who is receiving the active drug.

SCOTS2 treats various diseases of the retina and optic nerve. In addition to Stargardt, eye diseases that showed benefit included AMD (macular degeneration), retinitis pigmentosa, Usher, Cone-Rod, Rod-Cone, cone dystrophy, Bests’ dystrophy, nonperfusion retinopathy, retinal injury, retinal inflammation such as POHS or choroiditis. , certain diabetic retinopathies and certain post retinal detachment vision loss. Various optic nerve conditions have also responded, including glaucoma, NAION, LHON, ADOA, optic nerve ischemia, neuropathy, optic neuritis, optic atrophy, and optic nerve compression. To our knowledge, ALK-001 is only being studied for Stargardt disease at this time.

MD Stem Cells has treated many patients with a variety of eye diseases. He has published multiple medical and scientific articles. Patients and healthcare providers should feel confident that the physicians associated with MD Stem Cells have the knowledge and experience to carefully evaluate and, if appropriate, treat their retinal or optic nerve condition. All patients receive treatment; there is no placebo or dummy treatment.
New drugs are very important, but they can take years of careful clinical research before they are finally approved. This process may require patients to take a medication for long periods of time; some may be given a placebo.

Receive information on how to participate in SCOTS2 by emailing Dr. Levy at with your name, cell phone, email address, and a brief history of your disease. You can also use the contact page at or call directly at 203-423-9494. MD Stem Cells is not subsidized and is not a pharmaceutical company; This is a patient-sponsored study and patients pay for both treatment and travel.

Dr Steven Levy
DM stem cells
+1 203-423-9494
Visit us on social networks:

Leave a Comment